These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12552447)

  • 1. Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity.
    Russell ND; Hudgens MG; Ha R; Havenar-Daughton C; McElrath MJ
    J Infect Dis; 2003 Jan; 187(2):226-42. PubMed ID: 12552447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120.
    Wang X; Uto T; Akagi T; Akashi M; Baba M
    J Virol; 2007 Sep; 81(18):10009-16. PubMed ID: 17609261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation.
    Li F; Malhotra U; Gilbert PB; Hawkins NR; Duerr AC; McElrath JM; Corey L; Self SG
    Vaccine; 2006 Nov; 24(47-48):6893-904. PubMed ID: 16890329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Priming of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cell responses by dendritic cells loaded with HIV-1 proteins.
    Huang XL; Fan Z; Zheng L; Borowski L; Li H; Thomas EK; Hildebrand WH; Zhao XQ; Rinaldo CR
    J Infect Dis; 2003 Jan; 187(2):315-9. PubMed ID: 12552458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD8+ T cell responses to human immunodeficiency viruses type 2 (HIV-2) and type 1 (HIV-1) gag proteins are distinguishable by magnitude and breadth but not cellular phenotype.
    Gillespie GM; Pinheiro S; Sayeid-Al-Jamee M; Alabi A; Kaye S; Sabally S; Sarge-Njie R; Njai H; Joof K; Jaye A; Whittle H; Rowland-Jones S; Dorrell L
    Eur J Immunol; 2005 May; 35(5):1445-53. PubMed ID: 15832290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
    Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
    J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef.
    Thakar MR; Bhonge LS; Lakhashe SK; Shankarkumar U; Sane SS; Kulkarni SS; Mahajan BA; Paranjape RS
    J Infect Dis; 2005 Sep; 192(5):749-59. PubMed ID: 16088824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses.
    Malnati MS; Heltai S; Cosma A; Reitmeir P; Allgayer S; Glashoff RH; Liebrich W; Vardas E; Imami N; Westrop S; Nozza S; Tambussi G; Buttò S; Fanales-Belasio E; Ensoli B; Ensoli F; Tripiciano A; Fortis C; Lusso P; Poli G; Erfle V; Holmes H
    J Immunol Methods; 2012 Jan; 375(1-2):46-56. PubMed ID: 21963950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.
    Gorse GJ; Baden LR; Wecker M; Newman MJ; Ferrari G; Weinhold KJ; Livingston BD; Villafana TL; Li H; Noonan E; Russell ND;
    Vaccine; 2008 Jan; 26(2):215-23. PubMed ID: 18055072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.
    Cao H; Kaleebu P; Hom D; Flores J; Agrawal D; Jones N; Serwanga J; Okello M; Walker C; Sheppard H; El-Habib R; Klein M; Mbidde E; Mugyenyi P; Walker B; Ellner J; Mugerwa R;
    J Infect Dis; 2003 Mar; 187(6):887-95. PubMed ID: 12660934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design.
    Altfeld M; Allen TM; Kalife ET; Frahm N; Addo MM; Mothe BR; Rathod A; Reyor LL; Harlow J; Yu XG; Perkins B; Robinson LK; Sidney J; Alter G; Lichterfeld M; Sette A; Rosenberg ES; Goulder PJ; Brander C; Walker BD
    J Virol; 2005 Apr; 79(8):5000-5. PubMed ID: 15795285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel simian immunodeficiency virus CTL epitopes restricted by MHC class I molecule Mamu-B*01 are highly conserved for long term in DNA/MVA-vaccinated, SHIV-challenged rhesus macaques.
    Su J; Luscher MA; Xiong Y; Rustam T; Amara RR; Rakasz E; Robinson HL; MacDonald KS
    Int Immunol; 2005 May; 17(5):637-48. PubMed ID: 15824066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
    Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens.
    Bazhan SI; Belavin PA; Seregin SV; Danilyuk NK; Babkina IN; Karpenko LI; Nekrasova NA; Lebedev LR; Ignatyev GM; Agafonov AP; Poryvaeva VA; Aborneva IV; Ilyichev AA
    Vaccine; 2004 Apr; 22(13-14):1672-82. PubMed ID: 15068850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of HLA-A*3101-restricted cytotoxic T-lymphocyte response to human immunodeficiency virus type 1 (HIV-1) in patients with chronic HIV-1 infection.
    Borghan MA; Oka S; Takiguchi M
    Tissue Antigens; 2005 Oct; 66(4):305-13. PubMed ID: 16185326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
    Goepfert PA; Tomaras GD; Horton H; Montefiori D; Ferrari G; Deers M; Voss G; Koutsoukos M; Pedneault L; Vandepapeliere P; McElrath MJ; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Baden LR; Harro C; Evans T;
    Vaccine; 2007 Jan; 25(3):510-8. PubMed ID: 17049679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of HIV-1-specific CD8+ T cell epitopes presented by HLA-A*2601.
    Satoh M; Takamiya Y; Oka S; Tokunaga K; Takiguchi M
    Vaccine; 2005 May; 23(29):3783-90. PubMed ID: 15893615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials.
    Hudgens MG; Self SG; Chiu YL; Russell ND; Horton H; McElrath MJ
    J Immunol Methods; 2004 May; 288(1-2):19-34. PubMed ID: 15183082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides.
    Bansal A; Gough E; Sabbaj S; Ritter D; Yusim K; Sfakianos G; Aldrovandi G; Kaslow RA; Wilson CM; Mulligan MJ; Kilby JM; Goepfert PA
    AIDS; 2005 Feb; 19(3):241-50. PubMed ID: 15718834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.